GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
=== Pathological mechanism === HLA-B27 is the most researched HLA-B allele due to its high relationship with spondyloarthropathies. Although it is not apparent how HLA-B27 promotes disease, theories exist and can be divided between antigen-dependent and antigen-independent categories.
In England, anatomy was the subject of the first public lectures given in any science; these were provided by the Company of Barbers and Surgeons in the 16th century, joined in 1583 by the Lumleian lectures in surgery at the Royal College of Physicians.
With varying potencies ranging from high to low, it is a partial agonist of several of the serotonin 5-HT1 receptors, including the serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptors, and is a partial agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The drug also interacts with α2-adrenergic receptors, with the sigma σ1 and σ2 receptors, with the imidazoline I1 receptor, and with other targets. Along with the preceding receptor interactions, MDMA is a potent partial agonist of the rodent trace amine-associated receptor 1 (TAAR1). Conversely however, due to species differences, it is far weaker in terms of potency as an agonist of the human TAAR1. The drug appears to act as a weak partial agonist of the human TAAR1 rather than as an efficacious agonist. In relation to the preceding findings, MDMA has been said to be essentially inactive as a human TAAR1 agonist. TAAR1 activation is thought to auto-inhibit and constrain the effects of amphetamines that possess TAAR1 agonism, for instance MDMA in rodents. Elevation of serotonin, norepinephrine, and dopamine levels by MDMA is believed to mediate most of the drug's effects, including its entactogenic, stimulant, euphoriant, hyperthermic, and sympathomimetic effects. The entactogenic effects of MDMA, including increased sociability, empathy, feelings of closeness, and reduced aggression, are thought to be mainly due to induction of serotonin release.
=== Wonder Beyond Belief: On Christianity (2018) === While Kermani's scholarly theses deal with Islamic tradition, he has since repeatedly turned his attention to Christianity. Particularly prominent and noteworthy in this regard is his Wonder Beyond Belief: On Christianity published in German in 2015 and in English in 2018. The book approaches Christianity in an aesthetic way—through thoughtful reflections on images by various Christian artists, especially from the Italian Baroque period. These self-contained, deeply researched art-historical essays open up exciting perspectives on central characteristics of Christianity and have met with great resonance. In a highly original approach to the cross, Kermani's characteristic linking of beauty and the terror of God can be found once again. Attracted by the aesthetic power of artist and sculptor Karl Schlamminger's cross sculpture, but also by the beauty and grace with which the cross is carried in Botticelli's depictions, Kermani is moved by the aesthetic power of the cross. However, he also recognizes the cross as a believer's approach to suffering itself—for example, when he compares the thieves on the cross to mercenaries who crucify agitators in Syria or Iraq today. Indeed, Kermani associates the cross with human victims throughout history, citing Jesus's lamenting accusation on the cross. He insists on not separating Jesus from ourselves and on discovering our own suffering in Jesus's suffering.
Sources: en.wikipedia.org
=== Other uses of the word "wholesale" === In the banking industry "wholesale" usually refers to wholesale banking, providing tailored services to large customers, in contrast with retail banking, providing standardized services to large numbers of smaller customers. In real estate, wholesaling is the act of contracting to purchase real property, and assigning that contract to an investor.
The app's operator suggested in court documents pertaining to its lawsuit to overturn the order that the retaliation was also for a ticket reservation prank waged by some users of the video platform that depressed attendance for a campaign rally he held in Tulsa, Oklahoma, that June. The executive order was blocked by federal courts in two separate cases on grounds that the sanctions likely violated IEEPA's informational materials exemption (under the Berman Amendment) and First Amendment protections applying to users of the apps. In February 2026, the Supreme Court held that the IEEPA did not authorize the president to set tariffs in Learning Resources, Inc. v. Trump. This decision reversed the tariffs implemented by Trump under IEEPA during his second term. Consequently, U.S. Customs established a new process—the Consolidated Administration & Processing of Entries (CAPE) system—to refund importers for voided IEEPA duties.
=== Major versus minor === Major cross-match: Here the Recipient serum is tested against donor packed cells to determine if the recipient has preformed antibodies against any antigens on the donor's cells. This is the required cross-match prior to release of a unit of packed cell from blood bank. Minor cross-match: Here the Recipient red cells are tested against donor serum to detect donor antibodies directed against a patient's antigens. This is no longer required. It is assumed that the small amount of donor serum and antibodies left in a unit of packed cells will be diluted in a recipient.
== B == Baeyer–Drewsen indigo synthesis (also commonly incorrectly named Baeyer–Drewson indigo synthesis) Baeyer–Villiger oxidation, Baeyer–Villiger rearrangement Bakeland process (Bakelite) Baker–Venkataraman rearrangement, Baker–Venkataraman transformation Baldwin's rules Bally–Scholl synthesis Balz–Schiemann reaction Bamberger rearrangement Bamberger triazine synthesis Bamford–Stevens reaction Barbier reaction Barbier–Wieland degradation Bardhan–Sengupta phenanthrene synthesis Barfoed's test Bargellini reaction Bartoli indole synthesis, Bartoli reaction Barton decarboxylation Barton reaction Barton–Kellogg reaction Barton–McCombie reaction, Barton deoxygenation Barton-Zard Synthesis Barton vinyl iodine procedure Baudisch reaction Bayer test Baylis–Hillman reaction Bechamp reaction Bechamp reduction Beckmann fragmentation Beckmann rearrangement Bellus–Claisen rearrangement Belousov–Zhabotinsky reaction Benary reaction Benedict's reagent Benkeser reaction Benzidine rearrangement Benzilic acid rearrangement Benzoin condensation Bergman cyclization Bergmann azlactone peptide synthesis Bergmann degradation Bergmann–Zervas carbobenzoxy method Bernthsen acridine synthesis Bestmann's reagent Betti reaction Biginelli pyrimidine synthesis Biginelli reaction Bingel reaction Birch reduction Bischler–Möhlau indole synthesis Bischler–Napieralski reaction Biuret test Blaise ketone synthesis Blaise reaction Blanc reaction Blanc chloromethylation Blum–Ittah aziridine synthesis Bodroux reaction Bodroux–Chichibabin aldehyde synthesis Bogert–Cook synthesis Bohlmann-Rahtz pyridine synthesis Bohn–Schmidt reaction Boord olefin synthesis Borodin reaction Borsche–Drechsel cyclization Bosch–Meiser urea process Bosch reaction Bouveault aldehyde synthesis Bouveault–Blanc reduction Boyland–Sims oxidation Boyer Reaction Bredt's rule Brook rearrangement Brown hydroboration Bucherer carbazole synthesis Bucherer reaction Bucherer–Bergs reaction Buchner ring enlargement Büchner–Curtius–Schlotterbeck reaction Buchwald–Hartwig amination Bunnett reaction Burgess reagent
Tenascin X (TN-X), also known as flexillin or hexabrachion-like protein, is a 450 kDa glycoprotein, a member of the tenascin family, that is expressed in connective tissues. In humans it is encoded by the TNXB gene. The TN-X protein is expressed in many parts of the human body, including the skin, muscles, kidneys, blood vessels, and digestive tract. Deficiencies in the TN-X protein due to mutations or not enough of it being produced (haploinsufficiency) can lead to a rare condition called classical-like Ehlers–Danlos syndrome (EDS). People with EDS may have loose joints and weak tissues because their bodies make defective collagen.
Sources: en.wikipedia.org
=== Prescription trends === In 2010, over 24.4 million prescriptions for generic fluoxetine were filled in the United States, making it the third-most prescribed antidepressant after sertraline and citalopram. In 2011, 6 million prescriptions for fluoxetine were filled in the United Kingdom. Between 1998 and 2017, along with amitriptyline, it was the most commonly prescribed first antidepressant for adolescents aged 12–17 years in England.
== External links == "Motixafortide (Code C88309)". NCI Thesaurus. Archived from the original on 18 January 2017. Clinical trial number NCT03246529 for "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)" at ClinicalTrials.gov
==== Staudinger ligation with azides ==== The Staudinger ligation of azides and phosphine has been used extensively in field of chemical biology. Because it is able to form a stable amide bond in living cells and animals, it has been applied to modification of cell membrane, in vivo imaging, and other bioconjugation studies.
which is a Bernoulli equation valid also for unsteady—or time dependent—flows. Here ∂φ/∂t denotes the partial derivative of the velocity potential φ with respect to time t, and v = |∇φ| is the flow speed. The function f(t) depends only on time and not on position in the fluid. As a result, the Bernoulli equation at some moment t applies in the whole fluid domain. This is also true for the special case of a steady irrotational flow, in which case f and ∂φ/∂t are constants so equation (A) can be applied in every point of the fluid domain. Further f(t) can be made equal to zero by incorporating it into the velocity potential using the transformation:
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.